Friday, September 15, 2023
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, dedicated to cutting-edge antibody technology innovation, and offering integrated antibody discovery and development solutions from concept to clinical trials ("Idea to IND" or "I to I™"), has recently revealed a new agreement with BeiGene, Ltd. This agreement aims to expand their collaborative efforts in the field of antibody discovery and leverages Nona's proprietary Harbour Mice® platform.
Within the framework of this collaboration, BeiGene will gain access to Nona Biosciences' exclusive Harbour Mice® platform, known for its fully human transgenic mice. Back in 2018, BeiGene had initially secured rights to utilize the proprietary Harbour Mice® H2L2 platform for multiple antibody programs. This expanded partnership between Nona and BeiGene will encompass the Harbour Mice® HCAb platform, which focuses on heavy chain-only antibody formats, further enhancing the efficiency and adaptability of therapeutic antibody discovery.
Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, expressed his enthusiasm for the extended collaboration with BeiGene in the field of antibody discovery. He emphasized that Nona's platform has been instrumental in accelerating innovative drug discovery for various stakeholders, including biotechnology and pharmaceutical companies, as well as academia, over the course of more than a decade. This expansion of the partnership reflects Nona's accumulated knowledge and expertise in the domain of drug discovery.
